In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C leads to $20mm for PrimeraDx

Executive Summary

Molecular diagnostics firm PrimeraDx raised $20mm in its Series C financing led by first-time backer CHL Medical Partners, which adds a board member. Returning shareholders Abingworth, InterWest Partners, Malaysian Technology Development Corp., MPM Capital, Burrill & Co., and Invus Group also participated. The company will use some of the funds to continue developing assays that are run on its ICEPlex system.
Deal Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies